Advertisement

Don't deserve this backlash, says Covaxin maker Bharat Biotech

Follow The Hawk on Google News+ Follow

Advertisement

Hyderabad: Bharat Biotech Chairman Krishna Ella said on Monday that the company does not deserve the backlash it is receiving in the light of the India's drugs regulator granting its coronavirus vaccine Covaxin approval for emergency use.

"Don't accuse us of inexperience. We are a global company... have manufactured 16 vaccines," he said, highlighting that "200 per cent honest" clinical trials were conducted.

Advertisement

Ella said the company conducts clinical trials not only in India but also many other countries.

Also readFSSAI to initiate action against Bisleri over unsafe water sample

His comments assume significance as Covaxin has been given an emergency approval despite allegedly only two of the required three trial phases being completed.

However, Ella pointed at the number of journal articles Bharat Biotech published and claimed that it was the first to identify Zika virus and file a patent for Zika and Chikungunya viruses.

Advertisement

Bharat Biotech was the only company to have a Bio Safety Level 3 (BSL- 3) production facility, he noted.

"We do 200 per cent honest clinical trials and yet we receive a backlash. If I am wrong, tell me. Some companies have branded me 'water'. I want to deny that. We are scientists," he said.

--IANS

Get The Hawk first on Google

Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.

Share this story

Advertisement

India eyes space-based drug development as scientists, startups explore microgravity researchRead next →India eyes space-based drug development as scientists, startups explore microgravity researchHealth · 22 Nov 2026, 03:08 PM IST